176034-12-1

Basic information

• Product Name: 3-[(E)-2-PYRIDIN-2-YLVINYL]ANILINE
• Synonyms: CHEMBRDG-BB 4003092;3-[(E)-2-PYRIDIN-2-YLVINYL]ANILINE;AKOS BC-0924;3-[(E)-2-pyridin-2-ylvinyl]aniline(SALTDATA: FREE);3-[(e)-2-(2-pyridinyl)vinyl]aniline
• CAS NO: 176034-12-1
• Molecular Formula: C13H12N2
• Molecular Weight: 196.25
• Mol File: 176034-12-1.mol

Chemical Properties

• Boiling Point: 378.9°C at 760 mmHg
• Flash Point: 211°C
• Appearance: /
• Density: 1.167g/cm³
• Vapor Pressure: 6.1E-06mmHg at 25°C
• Refractive Index: 1.713
• CAS DataBase Reference: 3-[(E)-2-PYRIDIN-2-YLVINYL]ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(E)-2-PYRIDIN-2-YLVINYL]ANILINE(176034-12-1)
• EPA Substance Registry System: 3-[(E)-2-PYRIDIN-2-YLVINYL]ANILINE(176034-12-1)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 176034-12-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H12N2/c14-12-5-3-4-11(10-12)7-8-13-6-1-2-9-15-13/h1-10H,14H2/b8-7+

Upstream product

• 55532-26-8 (E)-2-(3-nitrostyryl)pyridine 
• 100-69-6 2-vinylpyridine 
• 585-79-5 m-nitrobromobenzene 

Relevant articles and documents

Compounds for use as therapeutic agents affecting p53 expression and/or activity

The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.